Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Elixxer Ltd V.ELXR


Primary Symbol: V.ELXR.H Alternate Symbol(s):  ELIXF

Elixxer Ltd. is a Canada-based investment company. The Company has investments and activities in the legal cannabis sector. The Company is focused on investing opportunities in various sectors, with a priority on growth companies that are past the start-up phase.


TSXV:ELXR.H - Post by User

<< Previous
Bullboard Posts
Next >>
Post by whatsthewordon Oct 03, 2018 10:51am
56 Views
Post# 28737079

Tetra Bio-Pharma Moves PPP001 Closer to Commercial

Tetra Bio-Pharma Moves PPP001 Closer to CommercialTetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), in partnership with Ford’s Family Pharmacy and Wellness Center, have developed and implemented a pharmaceutical quality system for Canada’s first botanical-based prescription drug PPP001. The Good Manufacturing Practices, Regulatory Operations and Regions Branch, Health Canada completed the inspection of Ford’s manufacturing facility. A Drug Establishment License (DEL) was granted after having inspected and assessed the facility as being in compliance with the requirements of Divisions 2 to 4 of the Food and Drug Regulations thereby allowing Ford’s to conduct the fabrication, packaging and labeling of PPP001
<< Previous
Bullboard Posts
Next >>